| ￥7400 | |
| Z04509-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Conjugate | Biotin | ||||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized IL-23 alpha&IL-12 beta[Biotin], His & Avi, Human at 2μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml) can bind Human IL23R, hFc Tag. Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 21.7 kDa (IL-23 alpha) and 34.7 kDa (IL-12 beta) | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 24 kDa (IL-23 alpha) and 40-50 kDa (IL-12 beta) based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Immobilized IL-23 alpha&IL-12 beta[Biotin], His & Avi, Human, His Tag at 2 μg/ml (100 μl/Well) on streptavidin(5 μg/ml) precoated plate. Dose response curve for Human IL-23R, hFc Tag with the EC50 of 19.2 ng/ml determined by ELISA. »
Immobilized IL-23 alpha&IL-12 beta[Biotin], His & Avi, Human, His Tag at 0.5 μg/ml (100 μl/Well) on streptavidin(5 μg/ml) precoated plate. Dose response curve for Anti-IL-23 Antibody, hFc Tag with the EC50 of 2.2 ng/ml determined by ELISA. »
The purity of IL-23 alpha&IL-12 beta[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC. »
IL-23 alpha&IL-12 beta[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | The interleukin (IL)-12 family of cytokines, including IL12 and IL 23, play an important role in driving aberrant Th1 and Th17 immune responses in patients with Crohn's disease (CD). Targeting this pathway has opened new avenues for therapeutic intervention. The balance of proinflammatory cytokines interleukin (IL)-12 and IL-23 plays a key role in shaping the development of antitumor or protumor immunity. |
| Synonyms | IL23 alpha; IL12 beta; IL23 alpha&IL12 beta ; IL12 β; IL23 alpha&IL12 β; IL-23A&IL-12B; IL23A&IL12B |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
